important peptide hormones that are chiefly involved in the renal conservation of water and sodium (1:2).
Introduction
A major function of the kidney is to regulate body water and sodium balance. This function is achieved and finely regulated by a number of cellular and molecular processes, including tubular reabsorption of water and sodium through renal water channels (aquaporins) and sodium transporters under the tight control of hormones and nerves along with intracellular signaling pathways. Vasopressin and angiotensin II (AngII) are Moreover, transcriptional regulation of AQP2 in vivo is thought to be a result of vasopressin-induced increase in intracellular cAMP levels, which is capable of stimulating AQP2 gene transcription.
The renin-angiotensin-aldosterone system has also been demonstrated to play a critical role in the regulation of renal sodium and water metabolism through a variety of physiological pathways. In particular, AngII has known effects on the regulation of renal hemodynamics, glomerular filtration rate, aldosterone secretion, as well as more direct effects on renal tubule transport in the proximal tubule 10) . Moreover, several recent studies have demonstrated that AngII also has an important effect on the thick ascending limb (TAL) and collecting duct where AngII receptor mRNA and protein are present. For example, 1) AngII stimulates the activity of epithelial sodium channel (ENaC) in an isolated cortical collecting duct 11) ; 2) AngII induces vasopressin V2-receptor mRNA expression in cultured inner medullary collecting duct (IMCD) cells 12) ; and 3) AngII increases vasopressin-stimulated facilitated urea transport in the rat terminal IMCD 13) . These findings may suggest that AngII could play a role in the regulation of urinary concentration capacity. Moreover, we recently demonstrated that 1) AngII infusion in rats increased the expression of Na-H exchanger NHE3 and Na-K-2Cl cotransporter type 2 (NKCC2) in the medullary thick ascending limbs 14) ; 2) pharmacological blockade of the AngII AT1 receptor in rats co-treated with dDAVP and dietary NaCl-restriction resulted in an increase in urine production, a decrease in urine osmolality, and blunted the dDAVP-induced upregulation of AQP2 15) ; and 3) AngII plays a direct role in the regulation of AQP2 short-term targeting to the plasma membrane in the IMCD cells through AT1 receptor 16) .
The action of vasopressin and AngII is mediated by intracellular secondary messengers, which are mainly coupled to the cAMP/PKA and phosphoinositide pathways, respectively. It is well known that vasopressin induces an increase in intracellular cAMP levels 17) , Fig. 1 . Increased AQP2 targeting in response to short-term treatment of dDAVP in Brattleboro rats. A) AQP2 immunolabeling in the outer medullary collecting duct in kidneys of Brattleboro rats 2 hours after vehicle. B) AQP2 immunolabeling in the outer medullary collecting duct in kidneys of Brattleboro rats 2 hours after dDAVP treatment. OMCD, outer medullary collecting duct. 19) . Moreover, forskolin potentiates AngII-induced increase in intracellular [Ca 2＋ ] in an isolated cortical TAL 20) . Con- . Accordingly, we also demonstrated that vaso- . On the contrary, outer medullary NKCC2, NHE3, and Na,K-ATPase expression, which are chiefly involved in the active reabsorption of NaCl by the medullary thick ascending limb to maintain the countercurrent multiplication, was unchanged in response to dDAVP treatment, neither in the presence nor the absence of candesartan 15) . This suggests that the progressive blunting of the urine concentration in response to dDAVP seen in the rats co-treated with AT1 receptor blocker candesartan was primarily due to the prevention of a dDAVP-mediated increase in the osmotic water permeability in the outer and inner medullary collecting ducts, despite long-term dDAVP treatment. This is evidenced by the maintained (not increased) expression of AQP2 and p-AQP2, respectively.
dDAVP or AngII has a stimulatory effect on
AQP2 targeting to the plasma membrane in vitro
We demonstrated that AQP2 targeting to the plasma membrane of primary cultured IMCD cells was enhanced in response to acute dDAVP treatment, consistent with a number of previous in vitro and in vivo studies 8, [23] [24] [25] . Interestingly, we demonstrated that short-term treatment of AngII was also associated with increased AQP2 targeting to the plasma membrane in IMCD cells (Fig. 4) . Consistent with this, we demonstrated that cAMP levels increased in response to dDAVP in a dose-dependent manner in primary cultured IMCD cells 16) . Cyclic-AMP levels were also significantly increased by the single treatment of AngII and importantly, co-treatment with dDAVP ＋ AngII revealed an additive effect on cAMP production (Fig. 3) , p-AQP2 expression, and AQP2 targeting in primary cultured IMCD cells 16) . It should be noted that we demonstrated enhanced AQP2 targeting to the plasma membrane and increased cAMP levels in response to treatment of AngII, alone, with no significant changes in the p-AQP2 expression at 15 min after administration 16) . Since intracellular cAMP accumulation in IMCD cells is known to activate PKA, which subsequently increase AQP2 phosphorylation and AQP2
trafficking, an increase in p-AQP2 expression would be expected. However, at the time point used no significant changes were observed but it cannot be excluded that at some time point during the stimulation AQP2 phosphorylation may have been increased.
Moreover, it remains possible that only a minor fraction of AQP2 is subject to phosphorylation and at a level where fractional change escapes detection. Phosphoproteomic analysis of kidney tissues after dDAVP treatment is currently undertaken to examine the course of changes of the dDAVP-induced phosphorylated proteins.
Co-treatment with dDAVP and AngII
potentiates the cAMP production, p-AQP2
xpression, and AQP2 targeting in vitro
The actions of peptide hormones, vasopressin, and ] by IP3 and PKC activation by DAG.
Our findings revealed that AngII had an additive effect on the dDAVP-induced cAMP production (Fig 3) , ] and the cAMP levels are required for the AQP2 targeting and the accompanying increase in osmotic water permeability 23, 26) . The role of Ca 2＋ in the cross-talk between AngII and vasopressin was investigated in a previous study 19) using CHO cells . On the other hand, the same study also demonstrated that increased intracellular [Ca 2＋ ], induced by thapsigargin comparable to that induced by AngII, did not potentiate the vasopressindependent cAMP accumulation 19) , indicating that in- Another transduction pathway of AngII is PKC. We demonstrated that cAMP levels were significantly increased in response to short-term AngII treatment;
whereas, the levels were not increased in response to
AngII treatment in the presence of the PKC inhibitor staurosporine 16) . Moreover, imunocytochemistry demonstrated that AQP2 targeting to the plasma membrane was stimulated by AngII treatment alone, whereas it was attenuated in response to AngII .
Aldosterone increases urine production and decreases apical AQP2 expression in rats with diabetes insipidus
In addition to angiotensin II, aldosterone also plays a role in the regulation of body fluid homeostasis 22, 29, 30) .
Aldosterone has a complex interaction with vasopressin and this has been the subject in several previous studies 31, 32) . Synergistic effects of mineralocorticoids on vasopressin-induced osmotic water permeability have been shown in the toad urinary bladder and isolated perfused cortical collecting duct (CCD) from rabbits, but not in rats 31, 32) . Interestingly, in congenitally vasopressin-deficient Brattleboro rats, mineralocorticoiddeficiency (adrenalectomized Brattleboro rats substituted with glucocorticoids) causes a decreased diluting capacity compared to Brattleboro rats with intact adrenal glands, while the urine flow was not markedly affected 33) . Moreover, pharmacological interference with the renin-angiotensin system in Brattleboro rats using either captopril (an angiotensin converting enzyme inhibitor) or spirononlactone (a mineralocorticoid receptor blocker) has been shown to reduce urine production 34, 35) , suggesting that aldosterone may play a role for regulation of water excretion in vivo in the absence of vasopressin.
Recently, we demonstrated a marked increase in urine production in response to aldosterone treatment of rats with lithium-induced nephrogenic diabetes insipidus and in vasopressin-deficient Brattleboro rats with central diabetes insipidus 22) . Importantly, aldosterone treatment was associated with impaired or decreased apical trafficking of AQP2 in the connecting tubule (CNT) and CCD 22) . In addition to the decreased apical AQP2 expression in both the CNT and the initial CCD (iCCD), increased AQP2 expression was seen in the basolateral domains of the iCCD 22) . Consistent with this, aldosterone treatment was associated with increased free water clearance in both lithium-treated rats and Brattleboro rats. In contrast, spironolactone and aldosterone receptor antagonist treatment was associated with decreased urine production and an apparent increase in the AQP2 labelling in the apical plasma membrane domain, suggesting that the aldosterone receptor could be involved in the regulation of AQP2 trafficking and urine production in conditions of diabetes insipidus 22) .
Moreover, we demonstrated that long-term aldosterone infusion in normal rats receiving water intake ad libitum was associated with polyuria and decreased and CCD in addition to the sodium reabsorption.
Conclusion
Angiotensin II and aldosterone could play a role in the regulation of renal water reabsorption by changing intracellular AQP2 targeting and/or AQP2 abundance, in addition to vasopressin.
